News Releases

Keyword Search

Nov-03-2022
Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022
Oct-27-2022
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results
Oct-03-2022
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oct-03-2022
Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell Lymphoma
Sep-27-2022
Oncternal Therapeutics Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL
Sep-23-2022
Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
Sep-07-2022
Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Aug-09-2022
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results
Aug-02-2022
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results
Jul-14-2022
Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL